 Rushita Bagchi
Concepts (198)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histone Deacetylases | 8 | 2024 | 50 | 3.280 |
Why?
| | Myocardium | 11 | 2025 | 471 | 2.900 |
Why?
| | Fibroblasts | 12 | 2025 | 357 | 2.490 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 7 | 2018 | 42 | 2.200 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 396 | 1.510 |
Why?
| | Myofibroblasts | 9 | 2022 | 50 | 1.390 |
Why?
| | Gene Expression Regulation | 11 | 2022 | 1004 | 1.360 |
Why?
| | Collagen Type I | 4 | 2016 | 83 | 1.300 |
Why?
| | Adipocytes | 4 | 2024 | 127 | 1.060 |
Why?
| | Transcription Factors | 6 | 2024 | 570 | 0.920 |
Why?
| | Epigenomics | 1 | 2025 | 75 | 0.920 |
Why?
| | Myocytes, Cardiac | 5 | 2020 | 146 | 0.910 |
Why?
| | Animals | 37 | 2025 | 13485 | 0.900 |
Why?
| | Extracellular Matrix | 7 | 2025 | 116 | 0.830 |
Why?
| | Thermogenesis | 3 | 2024 | 31 | 0.830 |
Why?
| | Mice | 23 | 2024 | 5899 | 0.780 |
Why?
| | Obesity | 4 | 2022 | 1176 | 0.770 |
Why?
| | Energy Metabolism | 5 | 2022 | 315 | 0.730 |
Why?
| | Lysine | 1 | 2022 | 90 | 0.710 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2023 | 57 | 0.690 |
Why?
| | Genome, Human | 1 | 2020 | 121 | 0.640 |
Why?
| | Cardiomegaly | 2 | 2022 | 55 | 0.640 |
Why?
| | Adipose Tissue, Brown | 2 | 2023 | 45 | 0.610 |
Why?
| | Pulmonary Artery | 1 | 2020 | 142 | 0.590 |
Why?
| | Lung | 2 | 2022 | 479 | 0.550 |
Why?
| | Mice, Knockout | 6 | 2024 | 903 | 0.540 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 135 | 0.540 |
Why?
| | Signal Transduction | 9 | 2024 | 1724 | 0.530 |
Why?
| | NIH 3T3 Cells | 6 | 2018 | 52 | 0.520 |
Why?
| | Fatty Liver | 1 | 2018 | 141 | 0.520 |
Why?
| | Mice, Inbred C57BL | 9 | 2024 | 1888 | 0.510 |
Why?
| | Fibronectins | 1 | 2016 | 36 | 0.500 |
Why?
| | Gene Expression | 2 | 2015 | 618 | 0.490 |
Why?
| | Transcriptional Activation | 5 | 2018 | 127 | 0.480 |
Why?
| | Transforming Growth Factor beta | 6 | 2020 | 136 | 0.470 |
Why?
| | Nuclear Proteins | 3 | 2024 | 247 | 0.460 |
Why?
| | Luciferases | 1 | 2015 | 50 | 0.460 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 318 | 0.460 |
Why?
| | High-Throughput Screening Assays | 1 | 2015 | 39 | 0.460 |
Why?
| | Genes, Reporter | 1 | 2015 | 86 | 0.460 |
Why?
| | Quality of Life | 1 | 2020 | 893 | 0.430 |
Why?
| | Inflammation | 5 | 2020 | 649 | 0.420 |
Why?
| | Cells, Cultured | 7 | 2025 | 1583 | 0.420 |
Why?
| | Diet, High-Fat | 4 | 2025 | 230 | 0.400 |
Why?
| | Humans | 26 | 2025 | 52441 | 0.380 |
Why?
| | Smad Proteins | 1 | 2012 | 16 | 0.380 |
Why?
| | Oxidative Stress | 4 | 2022 | 805 | 0.380 |
Why?
| | Heart | 4 | 2020 | 352 | 0.360 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 389 | 0.360 |
Why?
| | Ventricular Remodeling | 2 | 2022 | 65 | 0.350 |
Why?
| | Fibrosis | 5 | 2025 | 198 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 7 | 2019 | 1558 | 0.320 |
Why?
| | Male | 17 | 2025 | 26874 | 0.320 |
Why?
| | Histones | 3 | 2024 | 315 | 0.310 |
Why?
| | Ischemia | 2 | 2021 | 150 | 0.300 |
Why?
| | Asthma | 4 | 2012 | 313 | 0.280 |
Why?
| | Promoter Regions, Genetic | 5 | 2018 | 465 | 0.270 |
Why?
| | Azepines | 2 | 2024 | 21 | 0.270 |
Why?
| | E-Box Elements | 3 | 2018 | 4 | 0.260 |
Why?
| | Triazoles | 2 | 2024 | 115 | 0.250 |
Why?
| | Disease Models, Animal | 6 | 2024 | 1483 | 0.240 |
Why?
| | Bioprinting | 1 | 2025 | 3 | 0.240 |
Why?
| | Transcription, Genetic | 2 | 2018 | 375 | 0.240 |
Why?
| | Anthracyclines | 1 | 2025 | 34 | 0.230 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2016 | 61 | 0.230 |
Why?
| | Heart Failure | 2 | 2022 | 527 | 0.230 |
Why?
| | Rats | 9 | 2019 | 3228 | 0.230 |
Why?
| | Phenotype | 6 | 2024 | 792 | 0.230 |
Why?
| | Base Sequence | 3 | 2016 | 632 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2024 | 35 | 0.220 |
Why?
| | 3T3-L1 Cells | 2 | 2022 | 13 | 0.220 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 390 | 0.220 |
Why?
| | Acetylation | 1 | 2024 | 96 | 0.220 |
Why?
| | A Kinase Anchor Proteins | 1 | 2024 | 3 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2024 | 53 | 0.220 |
Why?
| | Models, Biological | 3 | 2022 | 735 | 0.210 |
Why?
| | Muscle, Smooth | 3 | 2012 | 63 | 0.210 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 168 | 0.210 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2012 | 95 | 0.210 |
Why?
| | Catecholamines | 1 | 2023 | 44 | 0.210 |
Why?
| | Metabolome | 2 | 2021 | 100 | 0.200 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 9 | 0.190 |
Why?
| | Acylation | 1 | 2022 | 6 | 0.190 |
Why?
| | Macrophages | 1 | 2024 | 357 | 0.180 |
Why?
| | RNA-Binding Proteins | 2 | 2013 | 133 | 0.180 |
Why?
| | Reperfusion Injury | 1 | 2022 | 73 | 0.170 |
Why?
| | GATA4 Transcription Factor | 1 | 2020 | 11 | 0.170 |
Why?
| | Heart Murmurs | 1 | 2021 | 14 | 0.170 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 18 | 0.170 |
Why?
| | Acute Lung Injury | 1 | 2021 | 27 | 0.170 |
Why?
| | Myocardial Infarction | 1 | 2024 | 449 | 0.170 |
Why?
| | Leptin | 1 | 2022 | 148 | 0.170 |
Why?
| | Myofibrils | 1 | 2020 | 20 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2020 | 43 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 146 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 234 | 0.160 |
Why?
| | Pneumonia | 1 | 2021 | 122 | 0.160 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 149 | 0.160 |
Why?
| | Kidney | 2 | 2022 | 716 | 0.160 |
Why?
| | Heart Failure, Diastolic | 1 | 2019 | 1 | 0.150 |
Why?
| | Cardio-Renal Syndrome | 1 | 2019 | 2 | 0.150 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2019 | 47 | 0.150 |
Why?
| | Protein Binding | 3 | 2019 | 673 | 0.150 |
Why?
| | Actins | 2 | 2016 | 112 | 0.150 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 141 | 0.150 |
Why?
| | Isoenzymes | 1 | 2019 | 171 | 0.150 |
Why?
| | Chromatin | 1 | 2019 | 143 | 0.140 |
Why?
| | Gene Deletion | 2 | 2017 | 279 | 0.140 |
Why?
| | Transfection | 2 | 2018 | 365 | 0.140 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 34 | 0.140 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2018 | 59 | 0.140 |
Why?
| | Phosphorylation | 2 | 2017 | 536 | 0.140 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2019 | 180 | 0.140 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2017 | 4 | 0.140 |
Why?
| | Feedback, Physiological | 1 | 2017 | 13 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 56 | 0.140 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 83 | 0.130 |
Why?
| | Cell Line | 2 | 2016 | 1020 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2018 | 281 | 0.120 |
Why?
| | Smad3 Protein | 1 | 2016 | 9 | 0.120 |
Why?
| | Casein Kinase II | 1 | 2016 | 9 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 79 | 0.120 |
Why?
| | Serine | 1 | 2016 | 37 | 0.120 |
Why?
| | Female | 5 | 2025 | 28277 | 0.120 |
Why?
| | Connective Tissue Growth Factor | 1 | 2015 | 9 | 0.120 |
Why?
| | Biotin | 1 | 2015 | 46 | 0.120 |
Why?
| | Pancreas | 1 | 2015 | 71 | 0.120 |
Why?
| | Pyridones | 1 | 2015 | 35 | 0.110 |
Why?
| | Cloning, Molecular | 1 | 2015 | 181 | 0.110 |
Why?
| | Apoptosis | 1 | 2020 | 1120 | 0.110 |
Why?
| | Hypertension, Pulmonary | 2 | 2013 | 102 | 0.110 |
Why?
| | Angiotensin II | 1 | 2015 | 156 | 0.110 |
Why?
| | Adenylate Kinase | 1 | 2013 | 10 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2016 | 667 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 871 | 0.100 |
Why?
| | Genes, Dominant | 1 | 2012 | 22 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 217 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 133 | 0.090 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 778 | 0.090 |
Why?
| | Adipose Tissue | 2 | 2023 | 205 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2018 | 3449 | 0.080 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 415 | 0.070 |
Why?
| | Aged | 2 | 2022 | 10242 | 0.070 |
Why?
| | Mutation | 1 | 2012 | 1331 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2016 | 1013 | 0.060 |
Why?
| | Doxorubicin | 1 | 2025 | 246 | 0.050 |
Why?
| | Cell Movement | 2 | 2016 | 271 | 0.050 |
Why?
| | NF-kappa B | 1 | 2024 | 326 | 0.050 |
Why?
| | Middle Aged | 1 | 2018 | 13133 | 0.050 |
Why?
| | Adult | 1 | 2018 | 14205 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 182 | 0.050 |
Why?
| | Mice, Obese | 1 | 2022 | 22 | 0.050 |
Why?
| | Muscle Contraction | 2 | 2012 | 109 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 126 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2022 | 269 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 73 | 0.040 |
Why?
| | Body Weight | 1 | 2022 | 524 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2019 | 14 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 735 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 60 | 0.040 |
Why?
| | Oxadiazoles | 1 | 2019 | 9 | 0.040 |
Why?
| | Blood Pressure | 1 | 2022 | 525 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2019 | 89 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 94 | 0.040 |
Why?
| | Benzamides | 1 | 2019 | 52 | 0.040 |
Why?
| | Mitochondria, Heart | 1 | 2019 | 39 | 0.040 |
Why?
| | Estrogens | 1 | 2020 | 228 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 1365 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2018 | 57 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 236 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2019 | 150 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2018 | 128 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 147 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2019 | 259 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 558 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 573 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 357 | 0.030 |
Why?
| | Focal Adhesions | 1 | 2016 | 17 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1150 | 0.030 |
Why?
| | Echocardiography | 1 | 2019 | 409 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2015 | 69 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 22 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 1429 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2017 | 1134 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2013 | 48 | 0.020 |
Why?
| | Bronchoconstriction | 1 | 2012 | 6 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 204 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 2 | 0.020 |
Why?
| | Bronchial Hyperreactivity | 1 | 2012 | 5 | 0.020 |
Why?
| | Cellular Microenvironment | 1 | 2012 | 29 | 0.020 |
Why?
| | Hyperplasia | 1 | 2012 | 96 | 0.020 |
Why?
| | Chemokines | 1 | 2012 | 77 | 0.020 |
Why?
| | Hypertrophy | 1 | 2012 | 53 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 113 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2015 | 470 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2012 | 135 | 0.020 |
Why?
| | Diet | 1 | 2015 | 591 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 622 | 0.020 |
Why?
|
|
Bagchi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|